Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6004973 | NOVARTIS PHARM | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
US6004973 (Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
US5665772 | NOVARTIS PHARM | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
US7297703 | NOVARTIS PHARM | Macrolides |
Dec, 2019
(4 years ago) | |
US5665772 (Pediatric) | NOVARTIS PHARM | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
US7297703 (Pediatric) | NOVARTIS PHARM | Macrolides |
Jun, 2020
(3 years ago) | |
US8778962 | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
US8778962 (Pediatric) | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 8 months ago) | |
US8617598 | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Sep, 2022
(1 year, 7 months ago) | |
US8617598 (Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Mar, 2023
(1 year, 1 month ago) |
Afinitor Disperz is owned by Novartis Pharm.
Afinitor Disperz contains Everolimus.
Afinitor Disperz has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Afinitor Disperz are:
Afinitor Disperz was authorised for market use on 29 August, 2012.
Afinitor Disperz is available in tablet, for suspension;oral dosage forms.
Afinitor Disperz can be used as adjunctive treatment of patients with tsc-associated partial-onset seizures.
Drug patent challenges can be filed against Afinitor Disperz from 29 April, 2017.
The generics of Afinitor Disperz are possible to be released after 10 April, 2025.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-169) | Apr 10, 2025 |
New Indication(I-773) | Apr 10, 2021 |
Pediatric Exclusivity(PED) | Apr 29, 2014 |
Orphan Drug Exclusivity(ODE) | Oct 29, 2017 |
New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
New Indication(I-630) | Oct 29, 2013 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 29 April, 2017
Market Authorisation Date: 29 August, 2012
Treatment: Adjunctive treatment of patients with tsc-associated partial-onset seizures
Dosage: TABLET, FOR SUSPENSION;ORAL